Appraising iniparib, the PARP inhibitor that never was—what must we learn?
暂无分享,去创建一个
Johann S. de Bono | J. Bono | D. Tan | J. Mateo | Joaquin Mateo | Michael Ong | David S. P. Tan | Michael A. Gonzalez | M. Ong
[1] T. Fojo,et al. Why do phase III clinical trials in oncology fail so often? , 2012, Journal of the National Cancer Institute.
[2] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Daniel Birnbaum,et al. How basal are triple‐negative breast cancers? , 2008, International journal of cancer.
[4] E. Kun,et al. Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide. , 2009, Molecular medicine reports.
[5] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.
[6] Daowen Wang,et al. Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors , 2011, Molecular Cancer.
[7] Jan Lubinski,et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[9] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[10] I. Thompson,et al. Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Lillian L. Siu,et al. Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.
[12] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[13] A. Secord,et al. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. , 2012, Gynecologic oncology.
[14] D. Bergstrom,et al. Abstract A226: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. , 2011 .
[15] R. Wenstrup,et al. Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer , 2012, Cancer.
[16] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[17] P. Bach. Limits on Medicare's ability to control rising spending on cancer drugs. , 2009, The New England journal of medicine.
[18] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[19] E. Alli,et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.
[20] E. Kun,et al. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. , 1995, Biochemical pharmacology.
[21] U. Matulonis,et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Telfer,et al. Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft , 2011, Molecular Cancer Therapeutics.
[23] Robert Almassy,et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.
[24] I Judson,et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? , 2009, British Journal of Cancer.
[25] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Shapiro,et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells , 2012, Breast Cancer Research and Treatment.
[27] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[28] Roger Collier,et al. Rapidly rising clinical trial costs worry researchers , 2009, Canadian Medical Association Journal.
[29] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[30] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[31] Karol Sikora,et al. Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.
[32] John E. Harlan,et al. Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor , 2011, Clinical Cancer Research.
[33] Eric P Kaldjian,et al. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. , 2010, Genes & cancer.
[34] P. Workman. Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.
[35] C. Aring,et al. A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.
[36] P. LoRusso,et al. Translating Clinical Trials into Meaningful Outcomes , 2010, Clinical Cancer Research.
[37] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[38] K. Camphausen,et al. In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 , 2009, Clinical Cancer Research.
[39] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[40] F. Couch,et al. Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter* , 2008, Journal of Biological Chemistry.
[41] S. Powell,et al. BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II , 2007 .
[42] S. Powell,et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. , 2005, Cancer research.
[43] I. Roninson,et al. Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer , 2009 .
[44] Manash S. Chatterjee,et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.
[45] Alan Ashworth,et al. Translating cancer research into targeted therapeutics , 2010, Nature.
[46] L. Elmore,et al. Telomerase as a Target for Cancer Immunotherapy , 2003, Cancer biology & therapy.
[47] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[48] L. Hutchinson,et al. High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.
[49] J. Baselga,et al. SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). , 2012 .
[50] T. Fojo,et al. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. , 2012, Journal of the National Cancer Institute.
[51] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[52] S. Mathoulin-Pélissier,et al. How valid are claims for synergy in published clinical studies ? , 2022 .
[53] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[54] P. Workman. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.
[55] J. O’Shaughnessy,et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. , 2008, Clinical breast cancer.
[56] S. Lipsitz,et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[58] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Paul Workman,et al. Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.
[60] A. Tolcher,et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors , 2008 .
[61] C. Glenn Begley,et al. Raise standards for preclinical cancer research , 2012 .
[62] T. Yap,et al. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. , 2010, European journal of cancer.
[63] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[64] A. Ashworth,et al. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.
[65] Scott H. Kaufmann,et al. Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.
[66] G. Giaccone,et al. A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors , 2012, Clinical Cancer Research.
[67] J. Hainsworth,et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. , 2008, Clinical breast cancer.
[68] G. Mills,et al. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.
[69] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[70] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[71] E. Kun,et al. Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. , 2002, Biochemical pharmacology.
[72] Ian O Ellis,et al. Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] I. Roninson,et al. Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(−) triple-negative breast cancer (TNBC) cell line , 2011 .
[75] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[77] Jennifer L Moseley,et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors , 2008 .
[78] J. Manola,et al. PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. , 2013 .
[79] M. Telli. Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.